Endurance Bio Inc. Email Format
Biotechnology ResearchCalifornia, United States2-10 Employees
Endurance Bio Inc. is a biotechnology research company based in Palo Alto, California. It develops orally administered, small-molecule therapeutics, with candidates designated as T-168 and T-621. T-168 is in Phase 2 clinical development for neurodegenerative and metabolic diseases and has been selected for the Neuro-SysMed Parkinson's disease SLEIPNIR trial. T-621 is currently in IND enabling studies. The program centers on activating two transcriptional pathways, PGC-1a and TFEB, a dual mechanism relevant across neuro, metabolic, and other disease areas.